CONCORD, Mass., Sept. 11, 2019 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the World Bispecific Summit occurring September 17-19, 2019 in Waltham, MA. John Burke, PhD, Co-Founder, President and CEO, Applied BioMath is chairing a session titled "Pioneering Quantitative Models to Predict Optimal Bispecific Properties" at the conference Wednesday, September 18th at 4:45p.m.
Within this session are three, 30-minute presentations.
"These presentations highlight how computational systems pharmacology approaches can be applied to an array of projects within R&D, from early discovery to entering the clinic," said John Burke, PhD, Co-Founder, President and CEO, Applied BioMath. "They also show the flavor of diversity in approaches that exist for bispecifics in R&D and the value of incorporating mechanistic modeling throughout."
About Applied BioMath
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
SOURCE Applied BioMath, LLC